Skip to content
CompanySight
Company No. 12528378 · Incorporated 20 Mar 2020

Apellis UK Limited

Registered name: APELLIS UK LIMITED

Part of Apellis Pharmaceuticals, Inc. group

Apellis UK Limited made £4.7m revenue and £127k profit in the year to 31 Dec 2025.

Apellis UK Limited’s revenue fell 26% to £4.7m in the year to 31 Dec 2025, with £127k profit and 11 employees. The company is classified under “wholesale of pharmaceutical goods” and is based in London; we hold 3 years of its filed accounts.

Full P&L filedSection G · Wholesale and retail trade; repair of motor vehiclesSIC 46460Wholesale of pharmaceutical goods
Status
Active
Location
London, London
Age
6 yrs · since 2020
Type
Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Dec 2025

Key figures

Cash flow filed
Revenue
£4.7m
Growth ▼26.1%
Profit
£127k
Growth ▼31.5%
Profit margin
2.7%
Gross 100%
Employees
11
Change 0%
Profit / employee
£11.5k
Revenue/employee £431k
Profitable streak
3yrs
Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

3 filed years

Financial history

Multi-year financials, oldest to newest
Year to31 Dec 202331 Dec 202431 Dec 2025
DisclosureFull P&LFull P&LFull P&L
Profit & loss
Revenue (turnover)£6.6m£6.4m£4.7m
Gross profit£6.6m£6.4m£4.7m
Operating profit£218k£239k£163k
Profit before tax£218k£241k£167k
Profit after tax£163k£185k£127k
Profit (best available)£163k£185k£127k
Staff costs£3.8m£4.7m£4.1m
Employees (average)101111
Ratios
Profit margin2.5%2.9%2.7%
Gross margin100%100%100%
Revenue per employee£658k£583k£431k
Profit per employee£16.3k£16.8k£11.5k
Cash conversion284.9%58.4%−9.9%
Growth (year on year)
Revenue growth—▼2.5%▼26.1%
Profit growth—▲13.4%▼31.5%
Headcount growth—▲10%0%
Balance sheet — indirect signals, not revenue
Cash at bank−£318k£637k£880k
Net assets———
Current assets£2.3m£1.6m£1.4m
Debtors£1.9m£1m£562k
Cash from operations£620k£139k−£16.1k
SourceReports and Financial Statements · bulk data Nov 2025Reports and Financial Statements · bulk data Nov 2025Reports and Financial Statements · bulk data Sep 2026
Derived from the latest filing

How the business works

Profit margin
2.7%
Profit ÷ revenue.
Gross margin
100%
Gross profit ÷ revenue. High for software and services.
Revenue per employee
£431k
Revenue ÷ average employees.
Profit per employee
£11.5k
Profit ÷ average employees.
Cash conversion
−9.9%
Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue
—
Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue
—
Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue
11.8%
Money owed by customers. Low = customers pay quickly.
Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets
—
Now —
Cash at bank
▲38%
Now £880k
Headcount
0%
Now 11
Deferred income
—
Now —
Fixed assets
—
Now —
Corporate ownership

Group structure

Ownership chain

  1. Apellis Pharmaceuticals, Inc. (registered outside the UK register)ultimate parent75–100%
  2. Apellis UK Limitedthis company

Bands show the share of ownership each company holds in the one below it.

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Latest figures from Reports and Financial Statements for the year to 31 Dec 2025 (profit £127k), from the Companies House accounts bulk data published Sep 2026. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.